Clinical and Immunological Rationale for the Treatment of Chronic Nonbacterial Prostatitis/chronic Pelvic Pain Syndrome (Category IIIB) Due to Herpes Virus Infection
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to improve the effectiveness of treatment of patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (category IIIB) due to herpes virus infection by evaluating the clinical and immunological features of this pathology.
Materials and methods. 146 patients with chronic nonbacterial prostatitis (121 herpes virus etiology and 25 without detected viral infection) and 25 healthy young men were examined. The patients were divided into groups. Among all patients with herpesvirus etiology prostatitis, 46 patients had ejaculate DNA of herpes simplex virus 1/2 type (HSV 1/2 type), which made up the 1st comparison group, in 41 patients – DNA of cytomegalovirus (CMV) – II group comparison, and in 34 patients – the DNA of both viruses, respectively, the III comparison group. When assessing the immune status of patients, we studied the level of interferon-gamma (IFN-γ) in the blood serum and the content of secretory immunoglobulin A (sIgА) in the patients ejaculate; to assess the state of local inflammation, we studied the cytokine status of patients by examining the level of pro-inflammatory interleukin 6 (IL-6) and anti-inflammatory interleukin 10 (IL-10) in ejaculate patients. Symptoms of prostatitis were assessed by assessing the general condition by the total score (S+L) of the IPSS chronic prostatitis symptom scale. During the study, patients with prostatitis of viral etiology were treated, which were previously divided into subgroups of each of the groups that received traditional treatment according to the protocol and traditional treatment with the inclusion of Valtrovir, Overin, and Novirin, depending on the presence of the corresponding pathogen in the patients ejaculate. The above indicators of immunity and symptoms of prostatitis were compared after treatment with the corresponding indicators of patients with prostatitis of non-viral etiology (group IV control) and healthy patients (group V).
Results. According to the results of the study revealed significantly higher immunosuppression rates in patients with chronic abacterial prostatitis compared with healthy patients (p<0.05). When comparing the indicators of the immune and cytokine status in patients with viral and non viral prostatitis, significantly higher immunosuppression rates were identified respectively in the first, which confirms the role of herpes viruses in the development of prostatitis. After treatment (both traditional and advanced), all patients showed a positive dynamics of immunity and symptoms (p<0.05).However, when comparing the levels of IFN-γ, sIgА, IL-6, IL-10, scores (S+L) after both types of treatment, the best results were found in patients after advanced treatment (p<0.05).
Conclusion. The role of herpes viruses in the development of chronic nonbacterial prostatitis is proved. The etiopathogenetic therapy of patients with viral prostatitis is substantiated much more effective in comparison with traditional treatment.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Горпинченко И.И. Исследование клинической эффективности α1-адреноблокатора тамсулозина у мужчин при хроническом абактериальном простатите/синдроме хронической тазовой боли / И.И. Горпинченко, Ю.Н. Гурженко // Здоровье мужчины. – 2013. – № 2 (45). – С. 42–43.
Кузьмин В.Н. Диагностика, лечение и профилактика герпетической инфекции/ В.Н. Кузьмин // Лечащий врач. – 2000. – № 1. – С. 60–61.
Ершов Ф.И., Касьянова Н.В. Цитомегаловирусная инфекция (современные данные об эпидемиологии, клинике, диагностике и терапии) / Ф.И. Ершов, Н.В. Касьянова // Инфекции и антимикробная терапия. – 2002. – Т. 4, № 4. – С. 40–44.
Жибурт Е.Б. О механизмах активации ЦМВИ / Е.Б. Жибурт, Н.Б. Серебряная, И.В. Каткова [и др.] // Терапевтический архив. – 1997. – Т. 69, № 11. – С. 40–41.
Doble A, Harris JR, Taylor-Robinson D. Urology. 1991 Sep;38(3).
Strockij AV, Gavrusev AА, Rubanik LV, Poleshchuk NN. Is a nonbacterial prostatitis nonbacterial? Urologiia. 2015 Jul-Aug;(4).
Xiao J, Ren L, Lv H, Ding Q, Lou S, Zhang W, Dong Z. Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a casecontrol study. Urol Int. 2013;91(4):410-6.
Бреусов А.А., Кульчавеня Е.В., Чередниченко А.Г., Стовбун С.В. Что скрывается за диагнозом абактериальный простатит? // Вестник урологии. – 2017. – № 5 (2). – С. 34–41.
Tan SK, Cheng XS, Kao CS, Weber J, Pinsky BA, Gill HS, Busque S, Subramanian AK. Native kidney cytomegalovirus nephritis and cytomegalovirus prostatitis in a kidney transplant recipient. Transpl Infect Dis.2019 Feb;21(1).
Yoon GS, Nagar MS, Tavora F, Epstein JI. Cytomegalovirus prostatitis: a series of 4 cases. Int J Surg Pathol. 2010 Feb;18(1):55-9.
Дранник Г.Н. Введение в клиническую иммунологию (Илье Ильичу Мечникову посвящается) // Г.Н. Дранник, А.Г. Дранник. – 2015. – С. 55–67.
Dungwa N. Interferon found helpful in herpes genitalis case / N. Dungwa // South African Medical Journal. – 1997. – Vol. 87, № 4. – P. 475.
Исаков В.А. Иммунопатогенез и лечение генитального герпеса и хламидиоза: [руководство для врачей] / В.А. Исаков, Ю.В. Аспель. – М. - Н. Новгород: Лань, 1999. – 168 с.
Горпинченко І.І. Імунні фактори в патогенезі запальної та незапальної форм хронічного абактеріального простатиту / І.І. Горпинченко, К.Р. Нуріманов, В.С. Савченко, Т.В. Порошина, Г.М. Драннік // Здоровье мужчины. – 2017. – № 4 (63). – С. 69–73.
Walker A.K., Kavelaars A., Heijnen C.J., and Dantzer R. Neuroinflammation and Comorbidity of Pain and Depression // Pharmacol. Rev–2014. – № 66 (1). – P. 80–101.
Горпинченко І.І. Ефекти цитокінів еякуляту на показники патоспермії у хворих на хронічний абактеріальний простатит, ускладнений екскреторно-токсичним непліддям/ І.І. Горпинченко, Г.М. Драннік, Т.В. Порошина, К.Р. Нуріманов, В.С. Савченко, Л.І. Добровольська, І.І. Тарасова // Здоровье мужчины. – 2013. – № 3. – С. 181–184.
Горпинченко І.І., Порошина Т.В., Добровольська Л.І. Хронічний абактеріальний простатит: імунологічне дослідження еякуляту // Здоровье мужчины. – 2009. – № 2. – С. 80–82.
Бондаренко Г.М. Комплексне лікування геніального герпесу / Г.М. Бондаренко, Ю.В. Щербакова, І.М. Нікітенко, Т.В. Губенко // Дерматология та венерологія. – 2011. – № 1 (51). – С. 69–75.
Айзятулов Р.Ф. Вирусные заболевание кожи и слизистых оболочек (этиология, патогенез, клиника, диагностика, лечение, профилактика). – К., 2003. – 128 с.
Gupta R., Wald A., Krantz E., Selke S., Warren T., Vargas-Cortes M., Miller G., Corey L. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in genital tract. J Infect Dis. 2004 Oct 15;190(8). – Рр. 1374–1381.
Баранова И.П. Цитомегаловирусная инфекция // И.П. Баранова, О.А. Коннова, Ж.Н. Керимова, О.Н. Лесина, М.В. Никольськая, Л.И. Краснова // Учебное пособие для врачей. – 2008. – С. 7–10.
Попов В.Ф. Лекарственные формы интерферонов: монографія. – М.: «Триада-Х», 2002. –136 с.
Lasek W., Janyst M., Wolny R., Zapała Ł., Bocian K., Drela N. Immunomodulatory effects of inosine pranobex on cyto-kine production by human lymphocytes. Acta Pharm. 2015. 65(2). Р. 171-180. doi: 10.1515/acph-2015-0015.
